Back to results
US 2024/0360421 A1Published application
Materials and methods for the manufacture of pluripotent stem cells
AssigneeJanssen Biotech, Inc.
InventorsIqbal S GREWAL, Rajkumar GANESAN, Sanjaya SINGH
Life of this patent
Estimating the term…
Abstract
Provided here in are methods of producing induced pluripotent stem cells (iPSCs) and isolated population of produced induced pluripotent stem cells (iPSCs). Also provided herein are methods of treating a subject in need thereof using the produced iPSCs or pharmaceutical compositions comprising the produced iPSCs.
Claims15
1-61. (canceled)
A method of treating a subject in need thereof comprising:
- (i) obtaining a population of cells comprising peripheral blood mononuclear cells (PBMCs) from a subject;
- (ii) reprogramming γδ T cells in the population of cells to produce iPSCs according to the method of claim 45;
- and
- (iii) administering the produced iPSCs, or a pharmaceutical composition comprising the produced iPSCs to the subject, optionally after differentiating the iPSCs into one or more desired types of cells;
- wherein optionally the subject is a human;
- and
- wherein optionally the subject has a hyperproliferative disorder or a cancer of hematopoietic system.
4 more elements
63-66. (canceled)
A method of producing human induced pluripotent stem cells (iPSCs) comprising:
- a) a step for performing a function of contacting and culturing an isolated population of cells comprising γδ T cells with an activation culture to activate and enrich Vγ9Vδ2 γδ T cells within the isolated population of cells;
- wherein the activation culture comprises IL-15 and zoledronic acid;
- b) after step (a), a step for performing a function of purifying the Vγ9Vδ2-enriched γδ T cells from the isolated population of cells;
- c) a step for performing a function of transducing the purified Vγ9Vδ2-enriched γδ T cells with a viral vector encoding one or more reprogramming factors;
- and
- d) a step for performing a function of culturing the transduced cells under conditions suitable for reprogramming mammalian somatic cells to a pluripotent state, thereby producing iPSCs;
- wherein the produced iPSCs have rearranged TRG and TRD genes;
- wherein the produced iPSCs have TCR rearrangements containing Vγ9 and Vδ2 gene segments;
- wherein optionally the activation culture further comprises IL-2;
- wherein optionally the viral vector is a Sendai virus (SeV) vector;
- wherein optionally the method further comprises obtaining the isolated population of cells from a subject prior to step (a);
- and
- wherein optionally the isolated population of cells are peripheral blood mononuclear cells (PBMCs).
10 more elements
Dependencies are inferred from the claim text.